Dr. Reddy's Laboratories shares rise 1.51% and outperform sector rivals

11 articles · Updated · MarketWatch · Apr 28

Dr. Reddy's Laboratories closed at 1,354.75 rupees on Tuesday, with trading volume reaching 96,232, above its 50-day average.
The stock outperformed competitors like Lupin, Zydus Lifesciences, and Wockhardt, which all declined during a session where the BSE SENSEX Index fell 0.54%.
Despite the gain, Dr. Reddy's remains 1.68% below its 52-week high of 1,377.95 rupees achieved on June 12th, reflecting resilience amid broader market weakness.

Is Dr. Reddy's stock a bargain at a 40% discount, or is a major correction due?

After a drug rejection in Brazil, how secure is Dr. Reddy's global pipeline?

Beyond weight-loss drugs, what is Dr. Reddy's next billion-dollar breakthrough?

As rivals enter the market, how long can Dr. Reddy's lead in generic Ozempic last?

Can a pivot to nicotine gum truly shield Dr. Reddy's from its generics pricing crisis?

Will Middle East tensions and rising oil prices derail the pharma giant's growth?